Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guadecitabine and Nivolumab in Refractory CIMP+ Metastatic Colorectal Cancer
NCT03576963Phase 2Withdrawn
- Sponsor
- University of Southern California
- Start
- Jan 2020
- Primary completion
- Jan 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of guadecitabine in colorectal adenocarcinoma, sponsored by University of Southern California. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase 2 Dose at 28 days and 1 more. Planned start Jan 2020; status: withdrawn.
02
Drugs
guadecitabine
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT03576963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576963.